EOLS - Evolus Inc Stock Price, Fair Value and News

11.56USD-0.08 (-0.69%)Market Closed

Market Summary

USD11.56-0.08

Market Closed

-0.69%

EOLS Alerts

2 major insider sales recently.

EOLS Stock Price

View Fullscreen

EOLS RSI Chart

EOLS Valuation

Market Cap

669.8M

Price/Earnings (Trailing)

-10.86

Price/Sales (Trailing)

3.31

EV/EBITDA

-14.27

Price/Free Cashflow

-19.43

EOLS Price/Sales (Trailing)

EOLS Profitability

EBT Margin

-30.44%

Return on Equity

298.15%

Return on Assets

-32.64%

Free Cashflow Yield

-5.15%

EOLS Fundamentals

EOLS Revenue

Revenue (TTM)

202.1M

Rev. Growth (Yr)

39.76%

Rev. Growth (Qtr)

21.95%

EOLS Earnings

Earnings (TTM)

-61.7M

Earnings Growth (Yr)

10.13%

Earnings Growth (Qtr)

30.09%

Breaking Down EOLS Revenue

Last 7 days

-8.9%

Last 30 days

-17.3%

Last 90 days

-2.4%

Trailing 12 Months

38.3%

How does EOLS drawdown profile look like?

EOLS Financial Health

Current Ratio

2.33

Debt/Equity

-3.58

Debt/Cashflow

-0.46

EOLS Investor Care

Shares Dilution (1Y)

1.61%

Diluted EPS (TTM)

-1.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	156.4M	168.6M	184.7M	202.1M
2022	121.3M	132.4M	139.6M	148.6M
2021	58.3M	76.6M	85.6M	99.7M
2020	40.3M	45.7M	51.1M	56.5M
2019	0	0	0	34.9M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Evolus Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 27, 2024	moatazedi david	sold	-86,431	13.86	-6,236	see remarks
Mar 19, 2024	avelar rui	sold	-384,350	13.9242	-27,603	see remarks
Mar 19, 2024	moatazedi david	sold	-1,344,600	13.9242	-96,566	see remarks
Mar 19, 2024	beaver sandra	sold	-78,978	13.9242	-5,672	chief financial officer
Feb 22, 2024	beaver sandra	sold	-23,820	13.0812	-1,821	chief financial officer
Feb 22, 2024	moatazedi david	sold	-100,804	13.0812	-7,706	see remarks
Feb 22, 2024	avelar rui	sold	-23,820	13.0812	-1,821	see remarks
Feb 21, 2024	moatazedi david	acquired	-	-	61,202	see remarks
Feb 21, 2024	avelar rui	acquired	-	-	13,115	see remarks
Feb 21, 2024	beaver sandra	acquired	-	-	13,115	chief financial officer

Which funds bought or sold EOLS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 17, 2024	Stephens Consulting, LLC	unchanged	-	1,006	4,060	-%
Apr 15, 2024	Legato Capital Management LLC	unchanged	-	375,489	1,514,940	0.18%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	409	1,652	-%
Apr 09, 2024	Halpern Financial, Inc.	unchanged	-	1,715	6,790	-%
Apr 05, 2024	CWM, LLC	reduced	-96.33	-4,000	-	-%
Apr 05, 2024	GAMMA Investing LLC	added	22.56	1,743	6,692	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	new	-	1,907,160	1,907,160	0.01%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	105	105	-%
Mar 11, 2024	VANGUARD GROUP INC	added	9.07	6,329,550	30,995,200	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	60.69	1,339,420	2,912,870	-%

Are Funds Buying or Selling EOLS?

Are funds buying EOLS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EOLS

No. of Funds

EOLS Alerts

2 major insider sales recently.

Unveiling Evolus Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	5.1%	2,910,849	SC 13G
Feb 14, 2024	perceptive advisors llc	6.9%	3,963,424	SC 13G/A
Feb 14, 2024	tang capital partners lp	5.4%	3,097,399	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	9.3%	5,333,004	SC 13G/A
Feb 13, 2024	vanguard group inc	5.15%	2,943,512	SC 13G
Feb 12, 2024	first manhattan co. llc.	0.86%	490,000	SC 13G/A
Jan 29, 2024	blackrock inc.	5.8%	3,339,377	SC 13G
Nov 27, 2023	perceptive advisors llc	5.4%	3,086,604	SC 13G
Oct 18, 2023	medytox inc.	5.9%	3,381,326	SC 13G/A
Oct 04, 2023	flynn james e	0.00%	1,784	SC 13G/A

Recent SEC filings of Evolus Inc

View All Filings

Date Filed	Form Type	Document
Apr 03, 2024	8-K	Current Report
Mar 29, 2024	4	Insider Trading
Mar 21, 2024	4	Insider Trading
Mar 21, 2024	4	Insider Trading
Mar 21, 2024	4	Insider Trading
Mar 13, 2024	8-K	Current Report
Mar 11, 2024	424B5	Prospectus Filed
Mar 07, 2024	10-K	Annual Report
Mar 07, 2024	S-8	Employee Benefits Plan
Mar 07, 2024	8-K	Current Report

Peers (Alternatives to Evolus Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	351.1B	85.2B	-6.70%	-10.33%	9.99	4.12	6.46%	95.94%
MRK	317.1B	60.1B	2.45%	9.70%	868.73	5.27	1.40%	-97.49%
PFE	143.3B	46.5B	-8.14%	-36.93%	-103.22	3.08	42.59%	-114.62%
AMGN	140.8B	28.2B	-3.32%	6.70%	20.96	4.99	7.09%	2.52%
GILD	82.4B	27.1B	-9.93%	-21.39%	14.54	3.04	-0.60%	23.36%
TEVA	14.3B	15.8B	-4.27%	50.53%	-24.85	0.9	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	-0.96%	-17.31%	-319.58	0.87	4.58%	90.97%
ALKS	4.0B	1.7B	-14.12%	-18.81%	11.16	2.39	49.61%	324.78%
BHC	3.1B	8.8B	-9.85%	14.21%	-5.31	0.36	7.79%	-163.11%
AMPH	1.9B	644.4M	-13.30%	-10.60%	13.51	2.88	29.14%	50.51%
SMALL-CAP
TLRY	1.3B	743.2M	-9.90%	-28.22%	-3.8	1.8	24.65%	80.36%
TXMD	21.7M	1.3M	-17.90%	-49.05%	-2.11	16.65	-98.14%	-109.18%
ACRX	17.6M	-	-9.57%	32.48%	-0.96	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	-30.19%	-94.45%	-0.18	0.13	80.00%	43.08%
ACOR	472.0K	117.6M	-96.45%	-95.94%	0	0	-0.79%	-283.60%

Evolus Inc News

Latest updates

Evolus Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	22.0%	60,999,000	50,019,000	49,346,000	41,721,000	43,646,000	33,899,000	37,163,000	33,908,000	34,657,000	26,677,000	26,098,000	12,241,000	20,577,000	17,661,000	7,806,000	10,496,000	11,831,500	13,167,000	2,311,000
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,807,000	5,858,000	6,277,000	15,811,000	9,449,000	1,651,000
Costs and Expenses	9.7%	69,634,000	63,459,000	64,464,000	53,761,000	54,283,000	51,796,000	58,511,000	49,356,000	52,685,000	45,787,000	41,391,000	4,215,000	128,603,000	26,421,000	26,693,000	27,891,000	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,567,000	24,745,000	23,672,000	28,354,000	34,587,000	37,648,000
S&GA Expenses	-0.6%	43,058,000	43,328,000	41,174,000	37,384,000	36,729,000	34,794,000	36,875,000	33,442,000	33,267,000	31,673,000	26,463,000	20,665,000	27,393,500	21,944,000	17,553,000	31,300,000	30,285,000	30,897,000	34,892,000
R&D Expenses	-	-	-	-	-	-	-	-	468,000	423,000	301,000	499,000	841,000	719,500	350,000	145,000	507,000	418,000	693,000	509,000
EBITDA Margin	14.9%	-0.21	-0.25	-0.30	-0.37	-0.41	-0.50	-0.53	-0.52	-0.40	-1.52	-1.56	-2.12	-	-	-	-	-	-	-
Interest Expenses	7.6%	4,075,000	3,786,000	3,182,000	2,789,000	2,631,000	2,343,000	2,075,000	2,048,000	140,000	311,000	300,000	645,000	1,801,000	1,821,000	1,821,000	1,801,000	1,801,000	1,821,000	1,208,000
Income Taxes	341.7%	106,000	24,000	23,000	23,000	57,000	12,000	28,000	-2,000	9,000	12,000	9,000	12,000	-150,000	-27,000	-2,000	256,000	-128,000	-149,000	-227,000
Earnings Before Taxes	30.6%	-11,725,000	-16,899,000	-18,117,000	-14,768,000	-13,107,000	-20,264,000	-23,443,000	-17,503,000	-18,168,000	-19,421,000	-15,592,000	6,413,000	-110,844,000	-11,486,000	-21,127,000	-19,479,000	-14,636,000	-27,133,000	-37,794,000
EBT Margin	10.6%	-0.30	-0.34	-0.39	-0.46	-0.50	-0.57	-0.59	-0.58	-0.47	-1.63	-1.72	-2.35	-	-	-	-	-	-	-
Net Income	30.1%	-11,831,000	-16,923,000	-18,140,000	-14,791,000	-13,164,000	-20,276,000	-23,471,000	-17,501,000	-18,177,000	-19,433,000	-15,601,000	6,401,000	-110,694,000	-11,459,000	-21,125,000	-19,735,000	-14,508,000	-26,984,000	-37,567,000
Net Income Margin	10.5%	-0.31	-0.34	-0.39	-0.46	-0.50	-0.57	-0.59	-0.58	-0.47	-1.63	-1.72	-2.35	-	-	-	-	-	-	-
Free Cashflow	163.4%	604,000	-953,000	-13,318,000	-20,814,000	-9,640,000	-17,560,000	-21,119,000	-38,211,000	-9,437,000	-32,125,000	16,116,000	-8,335,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	12.5%	189	168	169	160	178	193	211	221	257	215	240	157	209	216	195	214	240	183	203	221	172
Current Assets	22.2%	112	92.00	96.00	84.00	101	116	134	143	179	138	162	78.00	128	132	108	126	152	95.00	116	139	94.00
Cash Equivalents	62.4%	63.00	39.00	42.00	31.00	54.00	66.00	84.00	107	146	108	132	22.00	103	85.00	30.00	35.00	110	39.00	30.00	54.00	93.00
Inventory	-37.6%	11.00	18.00	20.00	23.00	19.00	22.00	12.00	4.00	2.00	4.00	3.00	3.00	3.00	5.00	10.00	13.00	6.00	10.00	12.00	3.00	-
Net PPE	-2.0%	2.00	2.00	2.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	-	-
Goodwill	0%	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00	21.00
Liabilities	11.9%	210	187	176	153	159	163	164	153	176	118	134	134	282	181	151	152	161	166	162	146	87.00
Current Liabilities	-0.5%	48.00	49.00	41.00	41.00	47.00	51.00	52.00	41.00	58.00	71.00	87.00	88.00	180	13.00	19.00	23.00	24.00	26.00	23.00	9.00	5.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	74.00	74.00	74.00	73.00	73.00	73.00	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	74.00	74.00	74.00	73.00	73.00	73.00	-
Shareholder's Equity	-Infinity%	-20.69	-	-	7.00	18.00	29.00	47.00	67.00	82.00	97.00	106	23.00	-	35.00	44.00	63.00	79.00	17.00	41.00	75.00	84.00
Retained Earnings	-2.2%	-558	-547	-530	-512	-497	-484	-463	-440	-422	-404	-385	-369	-376	-265	-253	-232	-213	-198	-171	-134	-123
Additional Paid-In Capital	2.0%	539	528	524	519	516	514	511	508	505	502	491	393	303	300	298	295	293	216	213	209	207
Shares Outstanding	1.3%	58.00	57.00	57.00	57.00	56.00	56.00	56.00	56.00	56.00	48.00	44.00	37.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	405	-	-	-	423	-	-	-	423	-	-	-	120	-	-	-	239	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	188.0%	813	-924	-13,310	-20,587	-8,774	-17,051	-20,888	-38,199	-9,044	-32,125	16,116	-8,335	-2,266	-13,713	-13,945	-27,947	-15,922	-25,103	-33,158	-19,200	-12,039
Share Based Compensation	-4.3%	4,397	4,596	4,171	3,294	2,412	2,483	2,979	2,959	2,649	2,476	2,861	1,590	2,630	2,952	2,374	2,628	2,537	2,526	2,457	1,998	1,860
Cashflow From Investing	33.0%	-361	-539	-216	-511	-1,391	-899	-388	-261	-390	21.00	-386	4,785	19,701	29,301	9,380	-46,188	13,974	34,390	8,227	-80,025	-
Cashflow From Financing	1757.6%	23,522	-1,419	23,820	-1,282	-1,516	-759	-849	-1,022	47,894	8,163	93,836	-76,841	-	39,767	-315	-1,105	72,724	-460	853	60,430	-

EOLS Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Revenues	$ 202,085	$ 148,616
Operating expenses:
Cost, Product and Service [Extensible Enumeration]	Product revenue, net	Product revenue, net
Product cost of sales (excludes amortization of intangible assets)	$ 61,559	$ 55,887
Selling, general and administrative	164,944	141,840
Research and development	6,556	4,742
In-process research and development	8,869	2,000
Revaluation of contingent royalty obligation payable to Evolus Founders	(4,257)	(5,755)
Depreciation and amortization	5,133	3,722
Total operating expenses	251,318	213,946
Loss from operations	(49,233)	(65,330)
Other income (expense):
Interest income	860	119
Interest expense	(13,832)	(9,097)
Other income (expense), net	696	(9)
Loss before income taxes:	(61,509)	(74,317)
Income tax expense	176	95
Net loss	(61,685)	(74,412)
Other comprehensive loss:
Unrealized loss, net of tax	(90)	(337)
Comprehensive loss	$ (61,775)	$ (74,749)
Net loss per share, basic (in dollars per share)	$ (1.08)	$ (1.33)
Net loss per share, diluted (in dollars per share)	$ (1.08)	$ (1.33)
Weighted-average shares outstanding used to compute basic net loss per share (in shares)	56,918,721	56,065,297
Weighted-average shares outstanding used to compute diluted net loss per share (in shares)	56,918,721	56,065,297
Product revenue, net
Revenue:
Revenues	$ 199,721	$ 146,592
Service revenue
Revenue:
Revenues	$ 2,364	$ 2,024

EOLS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 62,838	$ 53,922
Accounts receivable, net	30,529	22,448
Inventories	10,998	18,852
Prepaid expenses	5,700	3,902
Other current assets	2,356	1,678
Total current assets	112,421	100,802
Property and equipment, net	2,087	2,616
Operating lease right-of-use assets	5,763	1,947
Intangible assets, net	47,110	48,597
Goodwill	21,208	21,208
Other assets	409	2,813
Total assets	188,998	177,983
Current Liabilities
Accounts payable	4,271	8,935
Accrued expenses	33,813	24,794
Accrued litigation settlement	0	5,000
Operating lease liabilities	1,377	1,320
Contingent royalty obligation payable to Evolus Founders	8,830	6,460
Total current liabilities	48,291	46,509
Operating lease liabilities	4,810	1,224
Contingent royalty obligation payable to Evolus Founders	36,200	39,850
Term loan, net of discount and issuance costs	120,359	71,879
Deferred tax liability	27	22
Total liabilities	209,687	159,484
Commitments and contingencies (Note 8)
Stockholders’ equity (deficit)
Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	0	0
Common Stock, $0.00001 par value; 100,000,000 shares authorized; 57,820,621 and 56,260,570 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	1	1
Additional paid-in capital	538,716	516,129
Accumulated other comprehensive loss	(427)	(337)
Accumulated deficit	(558,979)	(497,294)
Total stockholders’ equity (deficit)	(20,689)	18,499
Total liabilities and stockholders’ equity (deficit)	$ 188,998	$ 177,983

About Evolus Inc

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It serves self-pay aesthetic healthcare market. Evolus, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

CEO	Mr. David Moatazedi
WEBSITE	evolus.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	215

Evolus Inc Frequently Asked Questions

What is the ticker symbol for Evolus Inc? What does EOLS stand for in stocks?

EOLS is the stock ticker symbol of Evolus Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Evolus Inc (EOLS)?

As of Thu Apr 18 2024, market cap of Evolus Inc is 669.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EOLS stock?

You can check EOLS's fair value in chart for subscribers.

What is the fair value of EOLS stock?

You can check EOLS's fair value in chart for subscribers. The fair value of Evolus Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Evolus Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EOLS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Evolus Inc a good stock to buy?

The fair value guage provides a quick view whether EOLS is over valued or under valued. Whether Evolus Inc is cheap or expensive depends on the assumptions which impact Evolus Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EOLS.

What is Evolus Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, EOLS's PE ratio (Price to Earnings) is -10.86 and Price to Sales (PS) ratio is 3.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EOLS PE ratio will change depending on the future growth rate expectations of investors.